SCHEMBL2883502

SCHEMBL2883502

CCNN(C)CC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3971996 0.74
SCHEMBL15785545 0.73
SCHEMBL2883603 0.73
SCHEMBL17625045 0.73
SCHEMBL18769350 0.73
SCHEMBL24429917 0.73
SCHEMBL8315539 0.73
SCHEMBL25056336 0.73
SCHEMBL22652895 0.70 AOC3 (0.33)
SCHEMBL1792330 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2764860-A1 Cupuassu fatty acid amidoamines and their derivatives BASF SA (BR) 2014-08-13 EP claimed
US-8461072-B2 Late transition metal catalysts for olefin oligomerizations EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-06-11 US claimed
WO-2024081939-A2 GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2024-04-18 WO disclosed
US-20230331803-A1 CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS NOVO NORDISK A/S (DK) 2023-10-19 US disclosed
CN-107540565-B Preparation of N, N- (di) alkylaminoalkyl (meth) acrylamides or the corresponding esters and quaternary ammonium salts thereof 赢创运营有限公司 2022-10-21 CN disclosed
US-11195606-B2 Systems and methods for the determination of insulin sensitivity NOVO NORDISK A/S (DK) 2021-12-07 US disclosed
US-20210171475-A1 COMPOUNDS UCL BUSINESS LTD (GB) 2021-06-10 US disclosed
EP-2931225-B1 COOLING PREPARATIONS SYMRISE AG (DE) 2021-03-31 EP disclosed
WO-2020252397-A1 SMALL MOLECULE PROTEOLYSIS-TARGETING CHIMERAS AND METHODS OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2020-12-17 WO disclosed
EP-3126451-B1 AZETIDINE-SUBSTITUTED FLUORESCENT COMPOUNDS HUGHES HOWARD MED INST (US) 2020-09-09 EP disclosed
US-20200277449-A1 INJECTABLE HYBRID ALGINATE HYDROGELS AND USES THEREOF UNIV STRASBOURG (FR) 2020-09-03 US disclosed
WO-2014100734-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-06-26 WO disclosed
US-7670753-B2 Lithographic printing plate precursor EASTMAN KODAK COMPANY (US) 2010-03-02 US disclosed
US-20090053807-A1 Insulin and IGF-1 Receptor Agonists and Antagonists NOVO NORDISK A/S (DK) 2009-02-26 US disclosed
US-20080261146-A1 Lithographic Printing Plate Precursor EASTMAN KODAK COMPANY 2008-10-23 US disclosed
EP-1782127-B1 LITHOGRAPHIC PRINTING PLATE PRECURSOR EASTMAN KODAK CO (US) 2008-04-02 EP disclosed
US-20070203037-A1 Lubricant, magnetic recording medium and head slider FUJITSU LIMITED (JP) 2007-08-30 US disclosed
EP-1782127-A1 LITHOGRAPHIC PRINTING PLATE PRECURSOR EASTMAN KODAK COMPANY (US) 2007-05-09 EP disclosed
WO-2006023667-A1 LITHOGRAPHIC PRINTING PLATE PRECURSOR EASTMAN KODAK COMPANY (US) 2006-03-02 WO disclosed
EP-0023594-B1 TRANS-QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND MEDICAMENTS CONTAINING THESE DERIVATIVES F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1984-05-16 EP disclosed